Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.

Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting

The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.